Details:

Alternative Title:
JCO Precis Oncol
Publisher's site:
http://dx.doi.org/10.1200/PO.18.00225
Personal Author:
Katz, Steven J. ; Ward, Kevin C. ; Hamilton, Ann S. ; Abrahamse, Paul ; Hawley, Sarah T. ; ... More +
Katz, Steven J. ; Ward, Kevin C. ; Hamilton, Ann S. ; Abrahamse, Paul ; Hawley, Sarah T. ; Kurian, Allison W. Less -
Description:
Background

There are concerns that multigene panel testing compared with BRCA1/ 2-only testing after diagnosis of breast cancer may lead to unnecessary patient worry about cancer because of more ambiguous results.

Methods

Patients with breast cancer diagnosed from 2013 to 2015 and accrued from SEER registries in Georgia and Los Angeles were surveyed (n = 5,080; response rate, 70%), and responses were merged with SEER data and germline genetic testing and results. We examined patient reports of cancer worry by test type and results in 1,063 women who linked to a genetic test and reported undergoing testing.

Results

More than half of the sample (n = 640; 60.2%) received BRCA1/2-only testing versus 423 patients (39.8%) who had a multigene panel. A minority of tested patients reported substantial cancer worry after treatment: 11.1% (n = 130) reported higher impact of cancer worry, and 15.1% (n = 162) reported a high frequency of cancer worry (worrying often or almost always) in the past month. Impact of cancer worry did not substantively differ by test type, test result outcomes, or clinical or treatment factors. The odds ratio for higher impact of cancer worry was 0.81 (95% CI, 0.51 to 1.28) for multigene versus BRCA1/2-only testing. In a separate model, the odds ratios were 1.21 (95% CI, 0.54 to 2.68) and 0.90 (95% CI, 0.50 to 1.62) for pathogenic variant and variant of uncertain significance, respectively, versus a negative test (the reference group).

Conclusion

Compared with BRCA1/2 testing alone, multigene panel testing was not associated with increased cancer worry after diagnosis of breast cancer.


Subject:
[+]
Article

Source:
JCO Precis Oncol. 2018
Pubmed ID:
30656245
Pubmed Central ID:
PMC6333469
Document Type:
Journal Article
Funding:
HHSN261201000140C/CA/NCI NIH HHS/United States ; HHSN261201000035C/CA/NCI NIH HHS/United States ; P30 CA046592/CA/NCI NIH HHS/United States ; P01 CA163233/CA/NCI NIH HHS/United States ; U58 DP003875/DP/NCCDPHP CDC HHS/United States ; ... More +
HHSN261201000140C/CA/NCI NIH HHS/United States ; HHSN261201000035C/CA/NCI NIH HHS/United States ; P30 CA046592/CA/NCI NIH HHS/United States ; P01 CA163233/CA/NCI NIH HHS/United States ; U58 DP003875/DP/NCCDPHP CDC HHS/United States ; HHSN261201300015C/RC/CCR NIH HHS/United States ; HHSN261201000035I/CA/NCI NIH HHS/United States ; HHSN261201000034C/CA/NCI NIH HHS/United States ; U58 DP003862/DP/NCCDPHP CDC HHS/United States Less -
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:615cac81ac302f5d640064d0a2421f680a93cc2fb571da0579cd522faf803ca4
File Type:

Supporting Files

• 	nihms-1004668-f0001.gif	gif
  	nihms-1004668-f0001.jpg	jpeg
  	nihms-1004668-f0002.gif	gif
  	nihms-1004668-f0002.jpg	jpeg
  	nihms-1004668.nxml	xml

More +